Convection Enhanced Delivery in the Setting of High-Grade Gliomas
Development of effective treatments for high-grade glioma (HGG) is hampered by 1) the blood-brain barrier (BBB), 2) an infiltrative growth pattern, 3) rapid development of therapeutic resistance, and, in many cases, 4) dose-limiting toxicity due to systemic exposure. Convec-tion-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and in-crease therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Preprints.org - (2021) vom: 21. Apr. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nwagwu, Chibueze D. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.20944/preprints202103.0342.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg020127073 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg020127073 | ||
| 003 | DE-627 | ||
| 005 | 20230429203735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210315s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202103.0342.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg020127073 | ||
| 035 | |a (preprintsorg)10.20944/preprints202103.0342 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nwagwu, Chibueze D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Convection Enhanced Delivery in the Setting of High-Grade Gliomas |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Development of effective treatments for high-grade glioma (HGG) is hampered by 1) the blood-brain barrier (BBB), 2) an infiltrative growth pattern, 3) rapid development of therapeutic resistance, and, in many cases, 4) dose-limiting toxicity due to systemic exposure. Convec-tion-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and in-crease therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas. | ||
| 650 | 4 | |a Medicine & Pharmacology | |
| 650 | 4 | |a 610 | |
| 700 | 1 | |a Immidisetti, Amanda V. |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Adeagbo, Oluwasegun |e verfasserin |4 aut | |
| 700 | 1 | |a Adamson, David Cory |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonell, Anne-Marie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2021) vom: 21. Apr. |
| 773 | 1 | 8 | |g year:2021 |g day:21 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics13040561 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202103.0342.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 21 |c 04 | ||